MobiHealth News April 1, 2024
The new smartphone app, Rejoyn, will deliver treatment to patients taking antidepressant medication aimed at enhancing cognitive control of emotion.
Otsuka Pharmaceuticals and Click Therapeutics announced that Rejoyn, a smartphone-based prescription digital therapeutic for major depressive disorder (MDD), scored FDA clearance to be used as an adjunct to clinician-managed care.
Rejoyn is a six-week remote treatment program to help enhance cognitive control of emotion through a combination of clinically-validated cognitive emotional training and brief therapeutic exercises.
The prescription digital therapeutic is expected to be released in the second half of 2024 and available for patients 22 years and older who are taking an antidepressant medication.
“Rejoyn has a neuromodulatory mechanism designed to act like physical therapy for...
Today's Sponsors
Today's Sponsor